US Bancorp DE Purchases 3,866 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

US Bancorp DE lifted its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 142.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 6,576 shares of the company’s stock after buying an additional 3,866 shares during the quarter. US Bancorp DE’s holdings in Perspective Therapeutics were worth $88,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after purchasing an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Perspective Therapeutics during the first quarter valued at $15,511,000. Affinity Asset Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter valued at $6,069,000. Nicholson Wealth Management Group LLC bought a new stake in Perspective Therapeutics in the 3rd quarter worth about $21,390,000. Finally, Ally Bridge Group NY LLC purchased a new position in Perspective Therapeutics in the 2nd quarter worth about $3,951,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CATX. Oppenheimer reaffirmed an “outperform” rating and set a $22.00 price target on shares of Perspective Therapeutics in a report on Friday, October 11th. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of Perspective Therapeutics in a report on Thursday, October 24th. Bank of America began coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They set a “buy” rating and a $24.00 target price for the company. Truist Financial initiated coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $21.57.

Perspective Therapeutics Stock Down 11.7 %

Shares of CATX stock opened at $7.88 on Friday. Perspective Therapeutics, Inc. has a 1 year low of $2.28 and a 1 year high of $19.05. The company’s fifty day simple moving average is $12.55.

Perspective Therapeutics (NYSE:CATX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, sell-side analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.